The Dr. Miguel Burnier 20/20 Campaign in support of the Ocular Pathology Laboratory
We don’t do research as an intellectual exercise. We do research because there is a patient at the end of the day.
Nearly 500,000 Canadians are estimated to be living with a form of vision loss, which can have significant physical, emotional and financial impact on them and their families. With an aging population and the prevalence of vision loss in Canada expected to increase nearly 30 percent in the next decade, continued research in the field of ocular medicine is now becoming increasingly important in the hope of finding new treatments, and ultimately cures for these devastating illnesses.
The MUHC’s Ocular Pathology Laboratory strives to translate basic research findings into treatment options for patients living with ocular disease. It is an international leader in research, education and consultation and the lab’s expertise is complimented with some of the most innovative research equipment and technology available.
The MUHC’s Ocular Pathology Laboratory is one of the largest laboratories in the world conducting ocular metastasis research, and Dr. Burnier and his team, along with MUHC ophthalmologists, pathologists, dermatologists, and oncologists, are working to find a cure for uveal melanoma, the most common type of ocular cancer that is mostly found in adults. Uveal melanoma has a very low survival rate and almost half of those who are diagnosed will succumb to the disease because it has the ability to spread rapidly to other organs, particularly the liver, where it is often diagnosed. The lab is working to change this outcome by developing more effective treatments while also investigating how these cancer cells spread, which may have an impact on a range of other ocular diseases.
Each and every day, Dr. Burnier’s Ocular Pathology Laboratory works to remain at the forefront of ocular diseases. His leadership has helped the MUHC establish its position as an international centre and hub for clinical care and research related to eye disease.
To recognize Dr. Burnier’s outstanding achievements in this highly-specialized field, the MUHC Foundation has launched a $4 million campaign, which will include the creation of an endowment fund and support for the laboratory’s greatest needs. This essential investment will help the lab gain an even better understanding of the causes of eye disease while also facilitating potential early diagnoses for fatal ocular cancers such as uveal melanoma.
Your support of the Dr.Miguel Burnier 20/20 campaign will help:
- Recruit the world’s top talent and provide them with specialized training to develop new treatments for ocular diseases
- Establish an endowment fund to ensure a sustainable source of funding for continued innovation and leadership in the field of ocular disease
- Expand the lab’s expertise to include cornea and lens speciality (cataracts)
- Train the next generation of students on state-of-the-art equipment that is at the forefront of ocular care
- Improve patient outcomes by providing a more efficient and non-invasive procedure that reflects clinical ophthalmology best practices
- Create a visiting professorship that will specialize in OCT
- Invest in a state-of-the-art lens database to facilitate research and optimization of intraocular lenses used in cataract surgery
- Build a global network for training, research and clinical work in ocular diseases so that we can not only share but benefit from advances made in other countries and other populations
- Facilitate early diagnosis and develop personalized treatments and therapies for patients living with ocular diseases
How you can help
Director of Development
514-934-1934, ext. 71205